Skip to main content
Top
Published in: Journal of Cancer Survivorship 2/2011

01-06-2011

Racial differences in well-being and cancer concerns in prostate cancer patients

Authors: Sumedha Chhatre, Alan J. Wein, S. Bruce Malkowicz, Ravishankar Jayadevappa

Published in: Journal of Cancer Survivorship | Issue 2/2011

Login to get access

Abstract

Background

We analyzed the racial differences in physical well-being, social/family well-being, functional well-being, emotional well-being, and prostate cancer specific worry among men with clinically localized prostate cancer.

Methods

In this prospective cohort study, we recruited 121 Caucasian and 77 African American men with newly diagnosed prostate cancer. Participants completed the Functional Assessment of Cancer Therapy-Prostate (FACT-P) instrument at baseline and at 3, 6, 12 and 24 months follow-up. To determine the between and within group differences on all functional measures (physical well-being, social/family well-being, functional well-being, emotional well-being, and prostate cancer specific concerns), we used repeated measures ANOVA.

Results

Except for education, income and hospital type, the two racial groups had comparable socio-demographic and clinical attributes. At 3 months post-treatment, both groups experienced a decline in physical well-being and increase in prostate cancer specific concerns. Baseline values of these measures were not recovered by 24-month follow-up. In particular, lack of energy was the most prominent contributor to declining physical well-being. The ability to have and maintain an erection was the most severe prostate cancer specific concern. Lack of energy and concern regarding erection ability varied between the two groups over the follow-up period.

Conclusions

Our findings provide an insight into not only the overall racial variation in physical health and prostate cancer specific concern, but also the temporal differences in these measures that can occur over a 24-month follow-up. This has important implications for effective management of localized prostate cancer patients from different racial groups and merits further research.
Literature
1.
go back to reference Jemal A, Siegel R, Xu J, Ward E. Cancer facts and figures. CA A Cancer J Clin. 2010;60:1–25.CrossRef Jemal A, Siegel R, Xu J, Ward E. Cancer facts and figures. CA A Cancer J Clin. 2010;60:1–25.CrossRef
2.
go back to reference Shavers VL, Brown ML, Potosky AL, Klabunde CN, Davis WW, Moul JW, et al. Race/ethnicity and the receipt of watchful waiting for the initial management of PCa. J Gen Intern Med. 2004;19(2):146–55.PubMedCrossRef Shavers VL, Brown ML, Potosky AL, Klabunde CN, Davis WW, Moul JW, et al. Race/ethnicity and the receipt of watchful waiting for the initial management of PCa. J Gen Intern Med. 2004;19(2):146–55.PubMedCrossRef
3.
go back to reference Lubeck DP, Kim H, Grossfeld GD, Ray P, Penson DF, Flanders SC, et al. Health related quality of life differences between black and white men with PCa: Data from the cancer of the prostate strategic urologic research endeavor. J Urol. 2001;166:2281–5.PubMedCrossRef Lubeck DP, Kim H, Grossfeld GD, Ray P, Penson DF, Flanders SC, et al. Health related quality of life differences between black and white men with PCa: Data from the cancer of the prostate strategic urologic research endeavor. J Urol. 2001;166:2281–5.PubMedCrossRef
4.
go back to reference Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B. Geographic, age, and racial variation in the treatment of Local/Regional Carcinoma of the prostate. J Clin Oncol. 1995;13(1):93–100.PubMed Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B. Geographic, age, and racial variation in the treatment of Local/Regional Carcinoma of the prostate. J Clin Oncol. 1995;13(1):93–100.PubMed
5.
go back to reference Young CD, Roach M. Race and prostate cancer: What do we know? Prostate Journal. 2000;2(1):33–41.CrossRef Young CD, Roach M. Race and prostate cancer: What do we know? Prostate Journal. 2000;2(1):33–41.CrossRef
6.
go back to reference Underwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol. 2004;171:1504–7.PubMedCrossRef Underwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol. 2004;171:1504–7.PubMedCrossRef
7.
go back to reference Jayadevappa R, Johnson JC, Chhatre S, Wein AJ, Malkowicz SB. Ethnic variation in return to baseline values of patient reported outcomes in older prostate cancer patients. Cancer. 2007;109(11):2229–38.PubMedCrossRef Jayadevappa R, Johnson JC, Chhatre S, Wein AJ, Malkowicz SB. Ethnic variation in return to baseline values of patient reported outcomes in older prostate cancer patients. Cancer. 2007;109(11):2229–38.PubMedCrossRef
8.
go back to reference Johnson TK, Gilliland FD, Hoffman Rm, Deapen D, Penson DF, Stanford JL, et al. Racial/ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. J Clin Oncol. 2004;22(20):4193–201.PubMedCrossRef Johnson TK, Gilliland FD, Hoffman Rm, Deapen D, Penson DF, Stanford JL, et al. Racial/ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. J Clin Oncol. 2004;22(20):4193–201.PubMedCrossRef
9.
go back to reference Pettaway CA, Troncoso P, Ramirez EI, Johnston DA, Steelhammer L, Babaian RJ. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol. 1998;160:437–42.PubMedCrossRef Pettaway CA, Troncoso P, Ramirez EI, Johnston DA, Steelhammer L, Babaian RJ. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol. 1998;160:437–42.PubMedCrossRef
10.
go back to reference McNaughton-Collins M, Walker-Corkery E, Barry MJ. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer Screening and Treatment, 1990–2000. J Natl Cancer Inst Monogr. 2004;33:78–101.PubMedCrossRef McNaughton-Collins M, Walker-Corkery E, Barry MJ. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer Screening and Treatment, 1990–2000. J Natl Cancer Inst Monogr. 2004;33:78–101.PubMedCrossRef
11.
go back to reference Chan JM, Jou RM, Carroll PR. The relative impact and future burden of prostate cancer in the United States. J Urol. 2004;172:S13–7.PubMedCrossRef Chan JM, Jou RM, Carroll PR. The relative impact and future burden of prostate cancer in the United States. J Urol. 2004;172:S13–7.PubMedCrossRef
12.
go back to reference Litwin MS, Saigal CS (editors). Urologic diseases in American. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 2007; NIH Publication No. 07-5512. Litwin MS, Saigal CS (editors). Urologic diseases in American. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 2007; NIH Publication No. 07-5512.
13.
go back to reference Denberg TD, Beaty BL, Kim FJ, Steiner JF. Marriage and ethnicity predict treatment in localized carcinoma. Cancer. 2005;103:1819–25.PubMedCrossRef Denberg TD, Beaty BL, Kim FJ, Steiner JF. Marriage and ethnicity predict treatment in localized carcinoma. Cancer. 2005;103:1819–25.PubMedCrossRef
14.
go back to reference Litwin MS, McGuigan KA, Shpall AI, Dhanani N. Recovery of health related quality of life in the year after radical prostatectomy: early experience. J Urol. 1999;161:515–9.PubMedCrossRef Litwin MS, McGuigan KA, Shpall AI, Dhanani N. Recovery of health related quality of life in the year after radical prostatectomy: early experience. J Urol. 1999;161:515–9.PubMedCrossRef
15.
go back to reference Litwin MS, Melmed GY, Nakazon T. Life after radical prostatectomy: a longitudinal study. J Urol. 2001;166:587–92.PubMedCrossRef Litwin MS, Melmed GY, Nakazon T. Life after radical prostatectomy: a longitudinal study. J Urol. 2001;166:587–92.PubMedCrossRef
16.
go back to reference Eton DT, Lepore SJ, Helgeson VS. Early quality of life in patients with localized prostate carcinoma: an examination of treatment-related, demographic, and psychosocial factors. Cancer. 2001;92:1451–9.PubMedCrossRef Eton DT, Lepore SJ, Helgeson VS. Early quality of life in patients with localized prostate carcinoma: an examination of treatment-related, demographic, and psychosocial factors. Cancer. 2001;92:1451–9.PubMedCrossRef
17.
go back to reference Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy—prostate instrument. Urology. 1997;50:920–8.PubMedCrossRef Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy—prostate instrument. Urology. 1997;50:920–8.PubMedCrossRef
18.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Disease. 1987;40:373–83.CrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Disease. 1987;40:373–83.CrossRef
19.
20.
go back to reference Engels JM, Diehr P. Imputation of missing longitudinal data: a comparison of methods. J Clin Epidemiol. 2003;56:968–76.PubMedCrossRef Engels JM, Diehr P. Imputation of missing longitudinal data: a comparison of methods. J Clin Epidemiol. 2003;56:968–76.PubMedCrossRef
21.
go back to reference Oakes M. Statistical Inference. Chestnut Hill, Massachusetts: Epidemiological Resources; 1990. Oakes M. Statistical Inference. Chestnut Hill, Massachusetts: Epidemiological Resources; 1990.
22.
go back to reference Statistical Analysis System (SAS), Version 9.2 SAS Institute, Cary, NC. Statistical Analysis System (SAS), Version 9.2 SAS Institute, Cary, NC.
23.
go back to reference Stone PC, Murphy RF, Matar HE, Almerie MQ. Measuring the individual quality of life of patients with prostate cancer. Prostate Cancer Prostatic Dis. 2008;11:390–6.PubMedCrossRef Stone PC, Murphy RF, Matar HE, Almerie MQ. Measuring the individual quality of life of patients with prostate cancer. Prostate Cancer Prostatic Dis. 2008;11:390–6.PubMedCrossRef
24.
go back to reference Hoffman RM, Barry MJ, Stanford JL, Hamilton AS, Hunt WC, Collins MM. Health outcomes in older men with localized prostate cancer: results from the prostate cancer outcomes study. Am J Med. 2006;119:418–25.PubMedCrossRef Hoffman RM, Barry MJ, Stanford JL, Hamilton AS, Hunt WC, Collins MM. Health outcomes in older men with localized prostate cancer: results from the prostate cancer outcomes study. Am J Med. 2006;119:418–25.PubMedCrossRef
25.
go back to reference Joseph KJ, Alvi R, Skarsgard D, Tonita J, Pervez N, Small C, et al. Analysis of health related quality of life (HRQoL) of patients with clinically localized prostate cancer, 1 year after treatment with external beam radiotherapy (EBRT) alone versus EBRT and high dose rate brachytherapy (HDBRT). Radiat Oncol. 2008;20:1–5. Joseph KJ, Alvi R, Skarsgard D, Tonita J, Pervez N, Small C, et al. Analysis of health related quality of life (HRQoL) of patients with clinically localized prostate cancer, 1 year after treatment with external beam radiotherapy (EBRT) alone versus EBRT and high dose rate brachytherapy (HDBRT). Radiat Oncol. 2008;20:1–5.
26.
go back to reference Ukoli FA, Lynch BS, Adams-Campbell LL. The effect of radical prostatectomy on patient quality of life in African Americans. Radical prostatectomy and quality of life among African American. Ethn Dis. 2006;16:988–93.PubMed Ukoli FA, Lynch BS, Adams-Campbell LL. The effect of radical prostatectomy on patient quality of life in African Americans. Radical prostatectomy and quality of life among African American. Ethn Dis. 2006;16:988–93.PubMed
27.
go back to reference Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94(5):334–57.PubMed Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94(5):334–57.PubMed
28.
go back to reference Knight SJ, Siston AK, Chmiel JS, Slimack N, Elstein AS, Chapman BG, et al. Ethnic variations in localized prostate cancer: a pilot study of preferences, optimism, and quality of life among black and white veterans. Clin Prostate Cancer. 2004;3(1):31–7.PubMed Knight SJ, Siston AK, Chmiel JS, Slimack N, Elstein AS, Chapman BG, et al. Ethnic variations in localized prostate cancer: a pilot study of preferences, optimism, and quality of life among black and white veterans. Clin Prostate Cancer. 2004;3(1):31–7.PubMed
29.
go back to reference Soni MK, Cella D. Quality of Life and Symptom measures in oncology: an overview. Am J Manage Care. 2002;8:S560–73. Soni MK, Cella D. Quality of Life and Symptom measures in oncology: an overview. Am J Manage Care. 2002;8:S560–73.
30.
go back to reference Lee WB, McQuellon RP, Case LD, DeGuzman AF, McCullough Dl. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer. J Urol 162:403–6. Lee WB, McQuellon RP, Case LD, DeGuzman AF, McCullough Dl. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer. J Urol 162:403–6.
31.
go back to reference Ward-Smith P, Mehl J. Quality of life before and after prostatectomy as treatment for localized cancer. Urol Nurs. 2007;27(6):542–7.PubMed Ward-Smith P, Mehl J. Quality of life before and after prostatectomy as treatment for localized cancer. Urol Nurs. 2007;27(6):542–7.PubMed
Metadata
Title
Racial differences in well-being and cancer concerns in prostate cancer patients
Authors
Sumedha Chhatre
Alan J. Wein
S. Bruce Malkowicz
Ravishankar Jayadevappa
Publication date
01-06-2011
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 2/2011
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-011-0170-1

Other articles of this Issue 2/2011

Journal of Cancer Survivorship 2/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine